Key Takeaways
- HSBC moved Eli Lilly (LLY) from Hold to Reduce, lowering its price target from $1,070 down to $850
- Analyst Rajesh Kumar describes LLY as trading at “priced to perfection” levels following a 20% rise in the past year
- The bank reduced its obesity drug market TAM projection to $80–120bn by 2032, significantly below the consensus $150bn+ estimate
- Questions surround orforglipron’s commercial prospects, pricing sustainability, and dependence on direct consumer payments
- Shares declined 1.6% to $972.51 after the rating change; competitor Novo Nordisk (NVO) has dropped 52% during the same timeframe
Eli Lilly has demonstrated impressive momentum recently. The company gained 20% value over twelve months while competitor Novo Nordisk shed more than half its market capitalization, positioning LLY as the apparent champion in the weight-loss pharmaceutical arena. However, HSBC believes investor enthusiasm may have exceeded fundamentals.
Tuesday brought a rating change from HSBC analyst Rajesh Kumar, who shifted Lilly to Reduce from Hold while trimming his price target to $850 from $1,070. Shares retreated 1.6% to $972.51 following the announcement.
Kumar’s central thesis is straightforward: current valuations assume flawless execution with minimal margin for disappointment.
The analyst’s case builds on three primary pillars. First comes the question of market size. HSBC’s updated projection places the total addressable market at $80–120 billion by 2032. This figure sits substantially below the $150 billion-plus projection that has become standard among Wall Street analysts.
This discrepancy carries weight. Reduced market potential translates to constrained revenue expansion opportunities relative to what investors have already priced into the stock.
Oral Weight-Loss Drug May Face Commercial Challenges
The second pillar addresses Lilly’s forthcoming oral obesity treatment, orforglipron. The medication is slated for release this year and has captured significant market attention — Wall Street consensus projects 2026 sales between $1.1 billion and $1.3 billion.
HSBC views these forecasts as overly optimistic. Kumar observed that “the compliance and persistence of these drugs might disappoint,” while pointing out that projections seem tied to the $1.5 billion inventory position Lilly has accumulated in preparation for launch.
Pre-launch inventory accumulation demonstrates corporate conviction. Yet it simultaneously elevates risk if commercial performance falls short.
Competitive Environment Creates Pricing Headwinds
The third pillar centers on revenue per unit. Lilly confronts pricing reductions starting in 2026 due to intensifying competition, with HSBC highlighting “rising working capital intensity” and weakening “rebate dynamics” as cautionary indicators.
Kumar drew attention to the divergence between Lilly’s performance and Novo Nordisk’s trajectory — a pattern that has generated confusion among market observers. His analysis suggests Lilly’s superior results stem largely from cash-pay channels, where patients cover costs directly rather than through insurance reimbursement.
This revenue stream carries greater sensitivity to macroeconomic shifts and faces potential disruption from AI-driven labor market transformations, according to HSBC’s assessment.
HSBC maintains a constructive view on the healthcare sector broadly for the coming quarter. Within that context, however, Kumar characterizes Lilly’s risk-reward profile as unattractive given present valuation levels.
LLY traded at $972.51 when the downgrade was published, representing more than $120 above HSBC’s revised $850 price target.
